Estrogen patches in short supply as demand for menopause hormone therapy grows [CNN]
Viatris Inc. (VTRS)
Company Research
Source: CNN
That relief is becoming harder to find – and doctors brace themselves for potentially more shortages to come. Manufacturers point to a rise in demand, driven by a greater awareness of menopause care and recent action by federal regulators to clarify the risks versus benefits of hormone therapies. The estradiol patch, a tiny square worn on the skin, may be discreet, but its impact is powerful. It delivers a consistent stream of estrogen to the body, which gets absorbed through the skin. The estrogen hormone naturally declines with age and when levels drop during menopause, symptoms can surge. During perimenopause , the transitional period before menopause, levels of estrogen can start to decrease. Padgett, a 49-year-old mother of two in Atlanta, said that she had to go those two weeks in January without medication because she could not find a pharmacy that had estrogen patches in stock. “It's just an inconvenience more than anything,” Padgett said. Her perimenopause symptoms
Show less
Read more
Impact Snapshot
Event Time:
VTRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTRS alerts
High impacting Viatris Inc. news events
Weekly update
A roundup of the hottest topics
VTRS
News
- FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia [Yahoo! Finance]Yahoo! Finance
- FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of PresbyopiaPR Newswire
- Earnings To Watch: Viatris (VTRS) Reports Q4 Results Tomorrow [Yahoo! Finance]Yahoo! Finance
- Estrogen patches in short supply as demand for menopause hormone therapy grows [CNN]CNN
- UBS Cite Efficient Capital Allocation and Rising Profits in Viatris Inc. (VTRS) Upgrade [Yahoo! Finance]Yahoo! Finance
VTRS
Earnings
- 11/6/25 - Beat
VTRS
Sec Filings
- 2/13/26 - Form 3
- 2/4/26 - Form SCHEDULE
- 2/3/26 - Form 8-K
- VTRS's page on the SEC website